相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma
Marlene Hennessy et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A. Ascierto et al.
EUROPEAN JOURNAL OF CANCER (2020)
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Giulia Parisi et al.
NATURE COMMUNICATIONS (2020)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
Meenu Sharma et al.
NATURE COMMUNICATIONS (2020)
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
Ioana Plesca et al.
FRONTIERS IN IMMUNOLOGY (2020)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab et al.
CANCER DISCOVERY (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso et al.
CANCER CELL (2020)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Celeste Lebbe et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.
Christy Osgood et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Omid Hamid et al.
CLINICAL CANCER RESEARCH (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study
Andrea Forschner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
J S Weber et al.
ANNALS OF ONCOLOGY (2019)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A. Ascierto et al.
JAMA ONCOLOGY (2019)
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
John Rossi et al.
BLOOD (2018)
Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies
Suman Mitra et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Biomarkers for Clinical Benefit of immune Checkpoint inhibitor Treatment-A Review From the Melanoma Perspective and Beyond
Kristina Buder-Bakhaya et al.
FRONTIERS IN IMMUNOLOGY (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Niki Karachaliou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
Deborah Charych et al.
PLOS ONE (2017)
The multifaceted roles of the invariant chain CD74-More than just a chaperone
Bernd Schroeder
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
David Klatzmann et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy
Frederic Van Gool et al.
BLOOD (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P. Dutcher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
T cell fitness determined by signal strength
AV Gett et al.
NATURE IMMUNOLOGY (2003)